Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New allergy pill shows promise for kids with constant stuffy nose

NCT ID NCT01425632

Symptom relief Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a medicine called TAU-284 in 490 children aged 7 to 15 who have year-round nasal allergies. The goal was to see if it reduces sneezing, runny nose, and congestion better than a placebo. The trial was completed and focused on symptom relief, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

490 people

The number who actually took part.

Start date

Aug 2011

Finished

Dec 2011

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 15 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 7 and 15 years * Patients with a weight of at least 20 kg * Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria * Patients with a mean rhinorrhea score of at least 2 and a mean total score for the three major nasal symptoms \[sneezing, rhinorrhea, and nasal congestion\] of at least 4 on the basis of symptoms recorded in the nasal allergy diary during the observation period Exclusion Criteria: * Patients with vasomotor rhinitis or eosinophilic rhinitis * Patients who have concurrent nasal disease that may affect the efficacy of TAU-284 * Patients with a history of any of the nasal surgical procedures * Patients who have a positive result for pollen antigens which are dispersed during the study period * Patients who have a positive result for dog dander or cat dander antigen * Patients with current or previous history of drug allergy * Patients who concurrently have renal function abnormalities that may cause safety problems

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Perennial allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

perennial allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Perennial allergic rhinitis

Contacts and locations

Locations

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Hokuriku, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

  • Reserch site

    Kyusyu, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.